Since its 2023 separation from Johnson & Johnson, Kenvue has demonstrated impressive earnings growth fueled by operational efficiencies and strategic marketing investments. The company’s global leadership in consumer health is anchored by a portfolio of iconic brands and a digitally enhanced supply chain. With shareholder approvals secured, the pending Kimberly-Clark merger introduces potential scale benefits but remains contingent on regulatory clearance. Investors should watch for execution on operational milestones and regulatory developments while monitoring evolving risks tied to litigation and supply chain dynamics.